CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for DRI Healthcare Trust is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

DRI Healthcare Trust
1 First Canadian Place
Suite 7250, 100 King Street West
Phone: (416) 863-1865p:416 863-1865 Toronto, ON  M5X 1B8  Canada Ticker: DHT.UNDHT.UN
Business Summary
DRI Healthcare Trust is a global pharmaceutical royalty monetization company. The Company's portfolio consists of 29 royalty streams on 23 products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. Its Royalty Assets include Ekterly, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Vonjo I, Vonjo II, Xolair, Zejula, Zytiga, and others. The Ekterly is an oral on-demand therapy for treating attacks associated with Hereditary Angioedema (HAE). The Eylea I is a vascular endothelial growth factor inhibitor initially indicated for the treatment of neovascular wet age-related macular degeneration. Natpara is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
6794 Patent owners and lessors
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board of Trustee, Chief Executive Officer Gary M.Collins 8/7/2024 1/22/2021
Chief Financial Officer ZaheedMawani 10/1/2025 10/1/2025
Trustee, Acting Chief Executive Officer of Manager AliHedayat 50 7/8/2024 1/22/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
3IJ0
DHT.UN

General Information
Number of Employees: 32 (As of 12/31/2025)
Outstanding Shares: 55,023,956 (As of 5/11/2026)
Stock Exchange: TSE


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, May 13, 2026